Showing results (131-140 of 190) with videos related to
Sort By:
Pageof 19
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon, Xiao-Dong Yang, Louis M Weiner, et al.Blood Advances|October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trialsChezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.European Urology|March 12, 2021
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell CarcinomaAndres F Correa, Opeyemi A Jegede, Naomi B Haas, et al.Blood|October 24, 2002
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman, Janet W Andersen, Charles A Schiffer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008Chezi Ganzel, Judith Manola, Dan Douer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphomaPeter H Wiernik, Izidore S Lossos, Joseph M Tuscano, et al.Blood|March 25, 2006
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993Hillard M Lazarus, Susan M Richards, Raj Chopra, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 23, 2013
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) studyUday B Dandamudi, Musie Ghebremichael, Jeffrey A Sosman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2003
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark, Michael B Atkins, Walter J Urba, et al.Pageof 19